{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:10:02Z","timestamp":1759734602376,"version":"build-2065373602"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"DOI":"10.7759\/cureus.93905","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:31:21Z","timestamp":1759732281000},"source":"Crossref","is-referenced-by-count":0,"title":["Tailoring Anticoagulant Therapy: Managing Interactions Between Carbamazepine and Direct Oral Anticoagulants (DOACs)"],"prefix":"10.7759","author":[{"given":"Tajuddin H","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj K","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon-Turriate","family":"Juan Pedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Giodano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11030049","article-title":"Venous thromboembolism prophylaxis in major orthopedic surgeries and factor XIa inhibitors","volume":"11","author":"Jones A","year":"2023","unstructured":"Jones A, Al-Horani RA. Venous thromboembolism prophylaxis in major orthopedic surgeries and factor XIa inhibitors. Med Sci (Basel). 2023, 11:49. 10.3390\/medsci11030049","journal-title":"Med Sci (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri N","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022, 14:1120. 10.3390\/pharmaceutics14061120","journal-title":"Pharmaceutics"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs","volume":"9","author":"Galgani A","year":"2018","unstructured":"Galgani A, Palleria C, Iannone LF, De Sarro G, Giorgi FS, Maschio M, Russo E. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018, 9:1067. 10.3389\/fneur.2018.01067","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2021.1908702","article-title":"Direct oral anticoagulants and therapeutic adherence: do not let your guard down","volume":"77","author":"Di Gennaro L","year":"2022","unstructured":"Di Gennaro L, Monaco M, Riccio C, et al.. Direct oral anticoagulants and therapeutic adherence: do not let your guard down. Acta Cardiol. 2022, 77:243-9. 10.1080\/00015385.2021.1908702","journal-title":"Acta Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12844","article-title":"Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: a case study of rivaroxaban and carbamazepine","volume":"11","author":"Ngo LT","year":"2022","unstructured":"Ngo LT, Yang SY, Shin S, et al.. Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: a case study of rivaroxaban and carbamazepine. CPT Pharmacometrics Syst Pharmacol. 2022, 11:1430-42. 10.1002\/psp4.12844","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1542063","article-title":"Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor Xa inhibitors in healthy volunteers","volume":"16","author":"Lenard A","year":"2025","unstructured":"Lenard A, Hermann SA, Stoll F, et al.. Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor Xa inhibitors in healthy volunteers. Front Pharmacol. 2025, 16:1542063. 10.3389\/fphar.2025.1542063","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.31083\/RCM39233","article-title":"Anticoagulation for stroke prevention in patients with atrial fibrillation: a review of the literature and current guidelines","volume":"26","author":"Vyas V","year":"2025","unstructured":"Vyas V, Vyas V, Sharma A, Ashok Kumar P. Anticoagulation for stroke prevention in patients with atrial fibrillation: a review of the literature and current guidelines. Rev Cardiovasc Med. 2025, 26:39233. 10.31083\/RCM39233","journal-title":"Rev Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar PL","year":"2022","unstructured":"Mar PL, Gopinathannair R, Gengler BE, et al.. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol. 2022, 15:e007956. 10.1161\/CIRCEP.121.007956","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231179439","article-title":"An updated pooled analysis of off-label under and over-dosed direct oral anticoagulants in patients with atrial fibrillation","volume":"29","author":"Shen NN","year":"2023","unstructured":"Shen NN, Ferroni E, Amidei CB, et al.. An updated pooled analysis of off-label under and over-dosed direct oral anticoagulants in patients with atrial fibrillation. Clin Appl Thromb Hemost. 2023, 29:10760296231179439. 10.1177\/10760296231179439","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.007971","article-title":"Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis","volume":"14","author":"Zhang XL","year":"2021","unstructured":"Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, Xu W. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2021, 14:e007971. 10.1161\/CIRCOUTCOMES.121.007971","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.09.053","article-title":"Dose of direct oral anticoagulants and adverse outcomes in Asia","volume":"139","author":"Ohno J","year":"2021","unstructured":"Ohno J, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y. Dose of direct oral anticoagulants and adverse outcomes in Asia. Am J Cardiol. 2021, 139:50-6. 10.1016\/j.amjcard.2020.09.053","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich N","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther. 2021, 110:1526-36. 10.1002\/cpt.2369","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry","volume":"68","author":"Steinberg BA","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, et al.. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol. 2016, 68:2597-604. 10.1016\/j.jacc.2016.09.966","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-18-0991","article-title":"Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry","volume":"83","author":"Murata N","year":"2019","unstructured":"Murata N, Okumura Y, Yokoyama K, et al.. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. Circ J. 2019, 83:727-35. 10.1253\/circj.CJ-18-0991","journal-title":"Circ J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen PB","year":"2017","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017, 356:j510. 10.1136\/bmj.j510","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan L","year":"2018","unstructured":"Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018, 16:1288-95.","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03015-7","article-title":"Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients","volume":"77","author":"Holm J","year":"2021","unstructured":"Holm J, Mannheimer B, Malmstr\u00f6m RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol. 2021, 77:409-19. 10.1007\/s00228-020-03015-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06907-8","article-title":"Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation","volume":"33","author":"Harskamp RE","year":"2019","unstructured":"Harskamp RE, Teichert M, Lucassen WA, van Weert HC, Lopes RD. Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2019, 33:615-23. 10.1007\/s10557-019-06907-8","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403034-tailoring-anticoagulant-therapy-managing-interactions-between-carbamazepine-and-direct-oral-anticoagulants-doacs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:31:22Z","timestamp":1759732282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403034-tailoring-anticoagulant-therapy-managing-interactions-between-carbamazepine-and-direct-oral-anticoagulants-doacs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,5]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.93905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,5]]}}}